Concord Biotech Limited (BOM:543960)
India · Delayed Price · Currency is INR 1,367.55
+12.90 (0.95%)
At close: Oct 6, 2026
Concord Biotech Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Concord Biotech stock has a consensus rating of "Buy" and an average price target of ₹1,551. The average 1-year stock price forecast is 13.39% higher than the current stock price, while the lowest is ₹1,268 (-7.28%) and the highest is ₹1,700 (+24.31%).
Price Target: ₹1,551 (+13.39%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Concord Biotech stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Apr '26 | Jun '26 | Jul '26 | Aug '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 1 | 1 | 2 | 2 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 5 | 5 |
Financial Forecast
Revenue This Year
12.93B
from 10.55B
Increased by 22.56%
Revenue Next Year
15.72B
from 12.93B
Increased by 21.58%
EPS This Year
32.66
from 25.01
Increased by 30.57%
EPS Next Year
42.54
from 32.66
Increased by 30.25%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.